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Abstract
Background: Eagerly awaiting the results of the Management of Myelomeningocele Study (MOMS) and with an
increasing interest in setting up intrauterine myelomeningocele repair (IUMR), the optimal management of patients
suffering from congenital myelomeningocele (MMC) has become a matter of debate again. We performed a cross-
sectional study at our referral-center for MMC to determine the outcome for our expectantly managed patients.
Materials and methods: A computed chart review at our institution revealed 70 patients suffering from MMC.
Forty-three patients were eligible for the study and analyzed further. A retrospective analysis was performed only in
patients that underwent MMC repair within the first two days of life and were seen at our outpatient clinic
between 2008 and 2009 for a regular multidisciplinary follow-up. Data were collected on: gestational age (GA) and
weight at birth, age at shunt placement and shunt status after the first year of life, radiological evidence for
Arnold-Chiari malformation (ACM) and tethered cord (TC), need for surgery for TC, bladder function, lower leg
function and educational level. Data were compared to published results for IUMR and to studies of historical
controls.
Results: Patients were born with MMC between 1979 and 2009 and are now 13.3 ± 8.9 (mean ± SD) years of age.
At birth, mean GA was 37.8 ± 2.3 weeks and mean weight was 2921.3 ± 760.3 g, both significantly higher than in
IUMR patients. Shunt placement in our cohort was required in 69.8% at a mean age of 16.0 ± 10.7 days, which was
less frequent than for historical controls. Amongst our cohort, radiological observations showed 57.1% had ACM II
and 41.9% had TC. Only two of our patients underwent a surgical correction for TC. Clean intermittent
catheterization was performed in 69.7% of our patients, 56.4% were (assisted) walkers and 64.1% attended regular
classes, both comparable to historical controls.
Conclusions: With a close and interdisciplinary management by pediatric surgeons, neurologists and urologists,
the long-term outcome of patients suffering from MMC can currently be considered satisfactory. With respect to
the known drawbacks of fetal interventions for mother and child, especially preterm delivery, the results of the
MOMS trial should be awaited with caution before proceeding with a complex intervention like IUMR.
Background
Myelomeningocele (MMC) is a mostly isolated congeni-
tal disorder of the central nervous system that has a
multifactorial etiology. Based on a prevalence of 10-15
per 10,000, more than 4,500 pregnancies are affected in
the European Union each year [1]. Its prevalence can be
reduced by 50-70% with maternal 400 μg folic acid sup-
plementation before conception and during the first tri-
mester [2,3]. Myelomeningocele is characterized by a
protrusion of the meninges and spinal cord through
open vertebral arches which results in varying degrees
of paralysis, mental retardation, bowel and bladder dys-
function as well as orthopedic disabilities [4]. After sur-
gical closure of the defect, many patients present with a
hydrocephalus that requires the placement of a ventricu-
lar shunt to prevent additional cerebral damage, which
again is associated with a high rate of complications like
dysfunction and infection [5]. Most patients are further
affected by an Arnold-Chiari malformation (ACM) due
to a downward movement of the hindbrain and obstruc-
tion of the normal egress of cerebrospinal fluid (CSF)
from the fourth ventricle that increases the 5-year-mor-
tality from 7.9% to 35% [6-8]. A high number of patients
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gressively worsens neurological function and frequently
requires surgical correction [9]. In 1990, the two-hit-
hypothesis for the pathogenesis of MMC was postulated
by Heffez et al: A defective spinal development is fol-
lowed by an intrauterine injury of the spinal cord due to
the exposure to amniotic fluid, meconium and urine, as
well as direct trauma and hydrodynamic pressure, thus
causing loss of neural tissue due to a progressive cell
toxicity over gestation [10-13].
Spina bifida is nowadays diagnosed prenatally in 70-
90% of cases mostly before 20 weeks of gestational age
(GA) by routine ultrasound scan [14,15]. If the ultra-
sound scan is positive, amniocentesis is performed to
rule out genetic syndromes and to measure alpha-feto-
protein (AFP) levels. Mostly, parents are counseled to
opt for expectant management or termination of preg-
nancy. In the United States, an intrauterine myelome-
ningocele repair (IUMR) can also be offered. The
concept of IUMR is based on the hypothesis that an
intrauterine protection of the exposed spinal cord as
well as the reduction of continuous intramniotic leakage
of CSF might prevent some of its secondary damage
[16,17]. Since the first intrauterine endoscopic repair in
1994, which was replaced by open surgical repair in
1997, about 400 open fetal interventions for MMC have
now been performed worldwide [4]. Preliminary results
suggest a reversal of hindbrain herniation, a decrease in
shunt-dependent hydrocephalus, an improvement in leg
function and an unaltered bladder function after IUMR
[4,18,19]. However, the technique remains of unproven
benefit and the reported findings might be explained by
selection bias and changing management indications
[20]. Therefore, the Management of Myelomeningocele
Study (MOMS), a multicenter, prospective, randomized
controlled trial of 200 patients (100 fetal repair, 100
postnatal repair), was set up in 2003 in the US (San
Francisco, Nashville and Philadelphia) to primarily
investigate death or the need for shunting by the age of
one year with and without fetal intervention in MMC
http://www.spinabifidamoms.com.
The objective of this study was to decide, whether it is
time to offer IUMR at our institution to patients diag-
nosed prenatally with MMC. Therefore, we performed a
retrospective data analysis on expectantly managed
patients with MMC that attended our hospital and com-
pared them to results obtained after IUMR at other
institutions and to historical controls as collected from
the literature.
Methods
Patient recruitment
A computed chart review was performed in February
2010 to conduct a descriptive and retrospective study
on information obtained from medical reports. Patients
were recruited to the study if they suffered from an
open spina bifida that was diagnosed pre- or postnatally
and underwent surgical repair within the first two days
of life to prevent further damage, e.g. by CSF leakage,
local infection or scarred shrinking, as generally
accepted.
Surgical repair of open spina bifida
After an ellipsoid incision of the zona cutanea,t h e
zona epithelioserosa was dissected. The dura was mobi-
lized completely and isolated from the fascia thoraco-
lumbalis.T h ezona epithelioserosa was excised and the
neural tube was reconstructed if possible using 10-0
absorbable single sutures. The dural layer was closed
in craniocaudal direction using a 6-0 or 7-0 absorbable
running suture, exceptionally inserting a dural patch.
After the water-tight closure of the dura, the defect
was covered by a wing-flap plasty. The fascia thoraco-
lumbalis was dissected and closed before the subcuta-
neous tissue and skin layer were sutured. A primary
stainless skin closure is essential in cases with extre-
mely large defects, for which we preferred longitudinal
incisions with mobilization of the skin and temporary
skin substitution if necessary. Postoperative monitoring
consisted of frequent clinical investigation, measure-
ment of head circumference and cranial ultrasound
examination.
Shunt placement
A ventricular-peritoneal shunt was placed only in the
case of symptomatic hydrocephalus, according to similar
criteria to that listed in Table 1.
Patient follow-up
All included patients were regularly seen at our outpati-
ent clinic for a multidisciplinary follow-up, including
consultation with a pediatric neurologist, pediatric urol-
ogist, pediatric orthopedists and pediatric surgeon. The
final follow-up was between 2008 and 2009 in order to
assess the patients’ current health status.
Data collection
Data were collected on: GA and weight at birth, neona-
tal death (defined as death within the first 28 days of
life), shunt status at the first year of life and age at
shunt placement, radiological presence of ACM and TC
as assessed postnatally by ultrasound and/or magnetic
resonance imaging, the need for surgery for TC, as well
as bladder function, lower leg function and educational
level. Satisfactory bladder function was defined as use of
clean intermittent catheterization (CIC) and satisfactory
educational level as regular attendance at kindergarten,
school or job.
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We performed computerized bibliographic searches
using Pubmed http://www.pubmed.gov and Embase
http://www.embase.com databases to identify studies
that report on outcome measurements after IUMR
("IUMR group”) and for postnatally-managed patients
with spina bifida ("historical controls”). If applicable, stu-
dies on which the MOMS trial had been based were
preferentially included as historical controls. After iden-
tification of matching studies, data extraction was per-
formed for outcomes as listed above. If the same
outcome was published several times, e.g. mean gesta-
tional age at birth, the cohort with the largest number
of patients was used for comparison.
Study groups
The study consisted of three groups: (1) retrospectively
assessed data on patients with open spina bifida that
u n d e r w e n tM M Cc l o s u r ea n df o l l o w - u pa to u ri n s t i t u -
tion ("Leipzig group”), (2) published data on patients
that underwent IUMR elsewhere ("IUMR group”)a n d
( 3 )p u b l i s h e dd a t ao np a t i e n t st h a tw e r eo p e r a t e dp o s t -
natally and managed elsewhere, preferentially providing
the basis for the MOMS trial ("historical controls”)
(Table 2).
Statistical analysis
Data collected from our cohort study ("Leipzig group”)
were analyzed assessing mean and standard deviation
( S D )f o rc o n t i n u o u sd a t a( G Aa n dw e i g h ta tb i r t h ,a g e
at shunt placement) and percentages for dichotomous
data (neonatal death, birth before 30 weeks GA, shunt
status at the first year of life, radiological presence of
ACM II and TC, use of CIC, lower leg function and
educational level). The collected results were compared
to data published for IUMR and historical controls,
respectively. For continuous data two-sided t-tests were
applied to compare published means against sample
means ("Leipzig group”). In none of the published arti-
cles were standard deviations presented. Therefore,
similar standard deviations to our studies were used,
assuming comparable distributions in similar popula-
tions. For nominal data contingency tables were gener-
ated from the total numbers of all study groups and
tested applying two-sided Fisher’s exact test. Regression
analysis was further performed to test the correlation
between birth year and prenatal diagnosis of our popula-
tion. All statistical analyses were performed using JMP 7
software (SAS Institute, Cary, NC, USA). Data are given
in raw numbers, percentage or mean ± SD if not indi-
cated differently. Results were considered statistically
significant at p < 0.05.
Results
Study population
The chart review revealed 70 patients suffering from
spina bifida. Of those, two underwent IUMR elsewhere,
five underwent MMC closure beyond the second day of
life, 10 had not undergone surgery for MMC at our hos-
pital or the operation date could not be identified and
10 patients were lost from follow-up. Therefore, data
from 43 MMC patients that underwent surgical correc-
tion for MMC within the first two days of life and had
been seen at our outpatient clinic between 06/2008 and
12/2009 were analyzed. All results are summarized in
Table 3. The 43 patients were born between 1979 and
2009 and were on average 13.3 ± 8.9 y of age at the
time of data analysis. 11.6% had thoracic, 79.1% lumbar
and 9.3% sacral lesions (Table 2).
Prenatal diagnosis and birth
Only 37.2% of our patients had been diagnosed prena-
tally with MMC. However, the number of prenatal diag-
noses significantly increased over time with a significant
correlation between prenatal diagnosis and birth year (p
< 0.0001). There were no neonatal deaths in our study
population compared to 4.5% after IUMR (p < 0.05)
[21]. Mean GA at birth in our population (37.8 ± 2.3
weeks) and of historical controls (37.0 weeks) was signif-
icantly higher than after IUMR (34.6 weeks; p <0 . 0 0 1 )
Table 1 Criteria for shunt placement
Criteria for Shunt placement (MOMS trial)
At least two of the following: Or:
An increase in the greatest occipitofrontal circumference adjusted for gestational
age and defined as crossing percentiles
Head circumference > 95
th percentile for gestational age
A bulging fontanelle*, split sutures or sunsetting sign Presence of marked syringomyelia (syrinx and expansion of spinal
cord) and ventriculomegaly (undefined)
Increasing hydrocephalus on two consecutive imaging studies determined by an
increase in ratio of biventricular diameter to biparietal diameter
§
Ventriculomegaly (undefined) and symptoms of Chiari
malformation (stridor, swallowing difficulties, apnea, bradycardia)
Persistent cerebrospinal fluid leakage from the myelomeningocele
wound or bulging at the repair site
Criteria for shunt placement as defined for the MOMS trial. *Bulging fontanelle: above the bone as assessed when the baby is in an upright position and not
crying.
§Defined by O’Hayon et al, 1998 [34]. Table adapted from Tulipan et al, 2004 [35].
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Study Group Reference Publication Year Study Site Study Period N patients Level of lesion (%)
thoracic lumbar sacral other
(1)
Leipzig group
Leipzig, Germany 1979-2009 43 11.6 79.1 9.3 -
(2)
IUMR group
Bruner [22] 1999 Vanderbilt, USA 1990-1997 29 median L4 (S-T12)
Tulipan [21] 2003 CHOP, Vanderbilt, USA 1983-2000 177 4.8 80.8 14.4 -
Johnson [24] 2003 CHOP,
USA
1998-2002 48 5 84 11 -
Bruner [25] 2004 Vanderbilt, USA 1997-2003 116 4.3 81.9 13.8 -
Brunner [23] 2005 Vanderbilt, USA 1997-2003 116 4.3 81.9 13.8 -
Koh
[27]
2006 Boston, USA 1979-2003 5 lumbosacral
Danzer [26] 2008 CHOP, USA 1998-2003 54 7.4 85.2 7.4 -
Danzer [18] 2009 CHOP, USA 1998-2003 54 7.4 81.5 11.1
Danzer [29] 2010 CHOP, USA 1998-2003 30 median L4 (T12-S1)
(3) Historical controls Bruner [22] 1999 Vanderbilt, USA 1990-1997 23 median L4 (S-T12)
Bowman [5] 2001 Chicago, USA 1975-1979 71 35.2 42.2 21.2 1.4
Tulipan [21] 2003 CHOP, Vanderbilt, USA 1983-2000 189 18.5 60.3 21.2 -
Koh
[27]
2006 Boston, USA 1979-2003 88 -
Aguilera [15] 2009 Bristol, UK 1999-2007 74 10.8 41.9 44.6 2.7
Summarized characteristics of included studies sorted by study group.
Table 3 Summarized results and statistical comparisons
(1)
Leipzig group
(2)
IUMR group
(3)
Historical controls
Statistical comparison
(p-value)
(2) vs (3) (1) vs (2) (1) vs (3)
Neonatal death (%) 0 4.5 [21] NA - < 0.05 -
GA at birth (wk) 37.8 ± 2.3 34.6 [21] 37.0 [22] - < 0.0001 ns
33.2 [22] 37.0 [22] < 0.001 [22] - -
GA < 30th wk (%) 0 11.8 [23] NA - < 0.05 -
Birth weight (g) 2921.3 ± 760.3 2512 [24] 3075 [22] - < 0.01 ns
2171 [22] 3075 [22] < 0.001 [22] - -
Shunt placement
≤ 1 y (%)
69.8 54.3 [25] 85.7 [21] < 0.0001 ns < 0.05
Age at shunt
placement (d)
16.0 ± 10.7 21.2 [24] - - < 0.05 -
12.5
$ 85.5 [22]
$ 5 [28]
$ < 0.01 [22] - -
Incidence
ACM II (%)
57.1 100
§ 75.7 [15] - - ns
Surgery TC (%) 11.1 29.6 [26] 32.4 [5] ns < 0.01 < 0.001
(Assisted) Walkers (%) 56.4
£ 92.6 [18]
# 59.2 [5]
¶ < 0.0001 < 0.0001 ns
Wheelchair users (%) 41.0
£ 7.4 [18]
# 40.8 [5]
¶ < 0.0001 < 0.0001 ns
Regular education (%) 64.1 NA 63.4 [5] - - ns
CIC (%) 69.7 NA 84.5 [5] - - ns
Summarized results of our data collection compared to published results for historical controls and IUMR applying the two-sided t-test or Fisher’s exact test at p
< 0.05. Data are presented in mean (± SD) or median and percentages. GA: gestational age, ACM: Arnold-Chiari malformation, TC: tethered cord, CIC: clean
intermittent catheterization. NA: not applicable, ns: not significant.
$median;
§ACM is one of the inclusion criteria for IUMR;
£mean age 13.3 ± 8.9 years,
#mean
age 67.0 ± 18.2 months,
¶mean age 21.7 years.
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and historical controls [21,22]. None of our patients but
11.8% of the children after IUMR were born before 30
weeks of gestation (p < 0.05) [23]. Mean weight at birth
in our group was 2921.3 ± 760.3 g, which was signifi-
cantly higher than after IUMR (2512 g; p < 0.01) and
not significantly different from historical controls (3075
g) [22,24].
Shunt status
Among historical controls, median 85.7% of the patients
required shunt placement within the first year of life,
which was significantly different from median 54.3%
after IUMR (p < 0.0001) and from 69.8% in our study
population (p < 0.05) [21,25]. On the contrary, there
was no significant difference for the need of shunting
within the first year of life between IUMR and our
population. However, the average age at shunt place-
ment was significantly higher after IUMR (mean 21.2
days) than in our study population (mean 16.0 ± 10.7
days; p < 0.05). Likewise, median age at shunt placement
was significantly higher after IUMR as compared to his-
torical controls (85 vs. 5 days; p < 0.01) [22,24].
Arnold-Chiari malformation and tethered cord
ACM II was radiologically diagnosed in 57.1% of our
patients, one patient presented with ACM I. The inci-
dence of ACM II was not different from historical con-
trols (75.7%) [15]. Among our patients 18 (41.9%)
presented with tethered cord and only two (11.1%) of
them had to undergo surgery for TC so far, which is
significantly less than after IUMR (29.6%; p <0 . 0 1 )a n d
less than for historical controls (32.4%; p < 0.001),
whereas the latter two did not differ significantly [5,26].
Quality of life
In our population 56.4% and in historical controls 59.2%
were assisted walkers that ambulate most of the time,
both of which are significantly different from 92.6% of
the patients after IUMR (p < 0.0001) [5,18]. Likewise,
40.8% of historical controls and 41.0% of our study
population were reliant on a wheelchair, which is signifi-
c a n t l ym o r et h a na f t e rI U M R( 7 . 4 % ;p < 0.0001). CIC
was regularly performed in 69.7% of our population and
similarly in 84.5% of historical controls [5]. Conversely,
all patients after IUMR but only 38% of historical con-
trols showed detrusor overactivity, suggesting that
IUMR is associated with a higher incidence of complete
denervation of the external urethral sphincter and detru-
sor overactivity [27]. A similar proportion of patients in
all three groups attended regular education, suggesting
adequate intellectual development (64.1%, 76.7% and
63.4% for Leipzig, IUMR and historical groups, respec-
tively) [5,18]. There was no significant difference
between shunted and non-shunted patients for the
attendance of regular education in our population (80%
vs. 58.6%). After IUMR, 67% of the patients had normal
cognitive language and personal-social skills, 20% had
mild and 13% significant delays at the age of two years,
23% were at risk for (significant) learning disabilities,
with the majority (85.7%) shunted [28,29].
Discussion
Myelomeningocele is a congenital anomaly that affects
about 1,500 infants per year in the US, of which recently
more than 90% survive the first year of life and about
75% will reach adulthood [5]. Even though MMC is a
non-lethal birth defect, it is the associated life-long mor-
bidity that motivates clinicians all over the world to
examine the value of fetal therapy. The aim of IUMR is
to improve postnatal morbidity and in particular neuro-
logical outcome by reduction of secondary injury to the
spinal cord [30]. This should be achieved by coverage of
the spinal defect to stop CSF leakage and to prevent
secondary damage, which in turn might allow normal
brain development. The initial fetoscopical approach
failed to show convincing benefit due to a high rate of
perinatal deaths, which could be ruled out when stan-
dard neurosurgical closure of the defect was performed
prenatally via a hysterotomy [30]. Since then, in about
400 cases of IUMR a reversal of hindbrain herniation, a
decrease in shunt-dependent hydrocephalus and an
improved leg function as compared to historical controls
have been suggested [4]. Those results will be confirmed
or rejected in the randomized controlled MOMS trial
that was initiated in 2003 in three major centers for
fetal surgery in the US to evaluate potential benefits
after prenatal versus postnatal MMC closure. While
keenly awaiting the results of the trial, we performed a
retrospective analysis on patients from our referral cen-
ter for MMC and reviewed the literature to compare the
outcomes of MMC patients treated at our institution
with published data from IUMR and historical controls.
Comparable to historical controls, mean gestational
age at birth in our patients was 37.8 weeks and no pre-
natal deaths were recorded. In contrast, after IUMR,
mean gestational age at birth was 34.6 weeks with 11.8%
of the infants born before 30 weeks of gestation, both
significantly different from historical controls and our
findings [21-23]. Perinatal mortality after IUMR was
5.9% [24]. As Bruner et al stated in 2005, virtually all
fetuses that underwent IUMR deliver preterm and more
than 10% even before 30 weeks, thus risking major mor-
bidity [23]. That prompts the question if the postulated
benefits of IUMR on hindbrain herniation, shunt-depen-
dent hydrocephalus and leg function justify the asso-
ciated risks for mother and child when IUMR in turn
may cause major morbidity and neonatal death due to
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[24]. Lethal complications due to chorioamnionitis, pla-
cental abruption and preterm premature rupture of the
membranes have been reported in particular for endo-
scopic IUMR, diminishing a fetoscopic approach for
MMC in the late 1990s [30]. To what extent surgical
risks and preterm delivery due to open IUMR contri-
butes to major morbidity and neonatal death cannot be
estimated from the available data but might be answered
by the MOMS trial.
The second main outcome of the MOMS trial, besides
neonatal death, is the need for shunting. As compared
to historical controls, the rate of shunting within the
first year of life was significantly lower in our cohort
and after IUMR, whereas the latter two did not differ
significantly. This observation is backed up by the find-
ings of others that reported shunt rates of 78% (n =
203) and 43.3% (n = 293), respectively, for postnatally-
managed patients [31,32]. One reason for the discre-
pancy in shunt rates might be the inconsistency in clini-
cal criteria for shunting, suggesting that the criteria
characterized for the MOMS trial should become gener-
ally accepted (Table 1).
Another important finding of our study was the dis-
crepancy in the rate of assisted walkers and wheelchair
users between our population/historical controls and
IUMR, for which 92.6% (assisted) walkers and only 7.4%
wheelchair users have been reported [18]. At first glance
this highly significant difference encourages the efforts
of IUMR. However, the mean age of the study popula-
tion was 21.7 years for historical controls, 13.3 years for
our population and only 67.0 months after IUMR. Our
results strengthen the finding that mobility decreases
from early childhood to the early teen years [33]. Bow-
man et al showed that the percentage of patients ambu-
lating the majority of time decreased from 76% at 0-5
years to 46% at 20-25 years, with a flattening beyond 10
years [5]. Assuming a similarp r o g r e s s i o nf o rc h i l d r e n
that underwent IUMR, less than 50% might continue to
be assisted walkers in their teens.
We are aware of the drawbacks of the conducted
study, which might be affected by the inhomogeneity of
study designs, study populations, outcome measure-
ments and treatment modality between centers as well
as by changes over time. Thus, our retrospectively-col-
lected data might be compared to results assessed in
varying populations, suggesting the comparison of
‘apples and oranges’. However, we performed a compre-
hensive review of the literature to identify the best
matching study groups for IUMR and historical controls
in the outcomes of our interest. Even though studies
varied in their study periods and sites, study populations
consisted of patients with similar levels of lesions, a fac-
tor known to importantly influence the clinical course
in MMC. Therefore, we assume that our cohort, as well
as the study population of included studies reflects
representative cross-sections of the ‘true’ MMC
population.
Conclusions
Considering the limitations of the presented study and
the data available today, a clear benefit of IUMR has not
yet been proven. The implementation of a close interdis-
ciplinary management following postnatal MMC closure
results in satisfactory long-term outcomes of patients
suffering from this defect. With regards to the well-
known challenges of fetal interventions for both, mother
and child, in particular preterm delivery, we actually do
not consider the implementation of IUMR at our insti-
tution as imperative and the results of the MOMS trial
should be awaited before initiating a complex interven-
tion like IUMR.
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